ArticleMedicine2026
Malignant neoplasm of bone and articular cartilage mortality trends in the United States: A 25-year population-based serial cross-sectional study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Malignant neoplasms of bone and articular cartilage (MNBAC) carry a disproportionately high mortality burden. Long-term mortality patterns may inform targeted public health interventions. This study examines MNBAC-related mortality among adults aged 25 years and older from 1999 to 2023. This study analyzed MNBAC-related mortality from 1999 to 2023 using the CDC WONDER Multiple Cause of Death database and International Classification of Diseases, Tenth Revision codes. Age-adjusted mortality rates (AAMRs) per 100,000 population were standardized to the 2000 US population. Trends were assessed using Joinpoint regression to estimate annual percent change (APC) and average annual percent change (AAPC). Analyses were stratified by age, sex, race, region, urbanization, and state. There were 33,724 MNBAC-related deaths in the United States from 1999 to 2023. The AAMR was 0.53 per 100,000 population (95% confidence interval [CI]: 0.49 to 0.56) in 1999 and 0.61 (95% CI: 0.58 to 0.64) in 2023, corresponding to a significant AAPC of 0.59% (95% CI: 0.30 to 0.87, P = .001). Joinpoint regression identified 3 segments (1999-2014, APC = -0.22%, P = .282; 2014-2018, APC = 4.26%, P = .087; 2018-2023, APC = 0.15%, P = .969), none of which reached statistical significance; the higher rates after 2014 should be interpreted with caution. Males had higher mortality than females; both sexes showed significant upward trends (AAPC: males 0.56%, P = .020; females 0.76%, P = .004). Non-Hispanic Whites exhibited the highest AAMRs, whereas non-Hispanic Others had the highest AAPC. The South recorded the highest AAMRs, while the West had the highest AAPC. Nonmetropolitan areas maintained higher AAMRs than metropolitan areas from 1999 to 2020, the last year for which urbanization-specific data were available, while a significant upward trend (2013-2020) was observed only in metropolitan areas. California reported the highest death counts. Individuals aged 85 + years had persistently elevated AAMRs over the entire study period. MNBAC-related mortality among US adults increased modestly from 1999 to 2023 and varied across demographic and geographic groups. Because death certificate data contain no information on tumor subtype, stage, treatment, or comorbidity, these findings are descriptive and hypothesis-generating: they identify subgroups carrying a disproportionate mortality burden but cannot determine reasons for these differences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.